{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:59:38Z","timestamp":1782136778642,"version":"3.54.5"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) and sickle cell disease (SCD) share features of endothelial and complement activation. Thus, we hypothesized that SCD is a risk factor for TA-TMA and that prehematopoietic cellular transplantation (HCT) markers of endothelial dysfunction and complement activation would be higher in patients with SCD. Children who underwent initial haploidentical or matched sibling donor HCT between January 2015 and June 2020 were included in this institutional review board\u2013approved, single institution, retrospective study. Of the 115 children, 52 had SCD, and 63 underwent HCT for non-SCD indications. There was no significant difference in severe grade 3 to 4 acute graft-versus-host disease (GVHD) between recipients of HCT with or without SCD. The non-SCD cohort had significantly more cytomegalovirus-positive recipients, radiation-containing preparative regimens, and peripheral blood stem cell graft sources (P \u2264 .05), all described risk factors for developing TA-TMA. Despite this, 7 of 52 patients (13%) with SCD developed TA-TMA compared with 1 of 63 patients (2%) without SCD (P\u00a0= .015). Risk was highest in those who underwent haploidentical HCT (odds ratio [OR], 33; 95% confidence interval [CI], 1.4-793.2). Adjusting for HLA match, GVHD, post-HCT viral infection, stem cell source, and myeloablation, SCD remained a risk for developing TA-TMA (OR, 12.22; 95% CI, 1.15-129.6). In available pre-HCT samples, there was no difference in complement biomarkers between those with SCD and those without, though patients with SCD did have significantly higher levels of markers of endothelial activation, soluble vascular cell adhesion molecule 1, and P-selectin. In conclusion, children with SCD merit careful screening for TA-TMA after HCT, particularly those receiving a haploidentical HCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008058","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T20:13:36Z","timestamp":1662668016000},"page":"1784-1795","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle","family":"Schoettler","sequence":"first","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Stenger","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Spencer","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Lutterman","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanah","family":"Rumbika","sequence":"additional","affiliation":[{"name":"3Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayre","family":"Jones","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Haight","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-9852","authenticated-orcid":false,"given":"Suhag","family":"Parikh","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Watkins","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmanan","family":"Krishnamurti","sequence":"additional","affiliation":[{"name":"4Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Williams","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-0800","authenticated-orcid":false,"given":"Satheesh","family":"Chonat","sequence":"additional","affiliation":[{"name":"1Children\u2019s Healthcare of Atlanta\/Aflac Cancer and Blood Disorders Center, Atlanta, GA"},{"name":"2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"issue":"16","key":"2023050514393302300_bib1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023050514393302300_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2023050514393302300_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy","volume":"95","author":"Roumenina","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2023050514393302300_bib4","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.V97.6.1584","article-title":"Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress\u2013mediated vasodilation","volume":"97","author":"Belhassen","year":"2001","journal-title":"Blood"},{"key":"2023050514393302300_bib5","first-page":"177","article-title":"Complement in sickle cell disease: are we ready for prime time?","volume":"12","author":"Varelas","year":"2021","journal-title":"Hematol Res Rev"},{"issue":"12","key":"2023050514393302300_bib6","doi-asserted-by":"crossref","first-page":"e96910","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"2023050514393302300_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2023050514393302300_bib8","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3324\/haematol.2020.262006","article-title":"Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease","volume":"105","author":"Chonat","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023050514393302300_bib9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2021-154132","article-title":"Complement activation during vaso-occlusive pain crisis in pediatric sickle cell disease","volume":"138","author":"Yoo","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023050514393302300_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023050514393302300_bib11","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2020.12.010","article-title":"Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case-control study","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2023050514393302300_bib12","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and complement activation as predictors of survival in adult allogeneic hematopoietic cell transplantation","volume":"5","author":"Gavriilaki","year":"2020","journal-title":"HemaSphere"},{"issue":"8","key":"2023050514393302300_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17474086.2021.1960816","article-title":"Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients","volume":"14","author":"Jodele","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"2023050514393302300_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"issue":"11","key":"2023050514393302300_bib15","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023050514393302300_bib16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2023050514393302300_bib17","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/bloodadvances.2019001315","article-title":"New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT","volume":"4","author":"Elfeky","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023050514393302300_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A\u00a0pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023050514393302300_bib19","doi-asserted-by":"crossref","first-page":"e27912","DOI":"10.1002\/pbc.27912","article-title":"Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease","volume":"66","author":"Bhunia","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2023050514393302300_bib20","doi-asserted-by":"crossref","first-page":"e26503","DOI":"10.1002\/pbc.26503","article-title":"Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies","volume":"64","author":"Abusin","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2023050514393302300_bib21","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023050514393302300_bib22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Veno-occlusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"1","key":"2023050514393302300_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023050514393302300_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/ije\/25.6.1107","article-title":"Basic methods for sensitivity analysis of biases","volume":"25","author":"Greenland","year":"1996","journal-title":"Int J Epidemiol"},{"issue":"6","key":"2023050514393302300_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an International Learning Collaborative","volume":"25","author":"de la Fuente","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023050514393302300_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2023050514393302300_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jama.2015.10029","article-title":"Prevalence of and trends in diabetes among adults in the United States, 1988-2012","volume":"314","author":"Menke","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"2023050514393302300_bib28","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"2023050514393302300_bib29","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In\u00a0vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"2023050514393302300_bib30","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1703026","article-title":"Serum levels of soluble adhesion molecules in stem cell transplantation-related complications","volume":"27","author":"Matsuda","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023050514393302300_bib31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.1995.tb05309.x","article-title":"Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections","volume":"91","author":"Bruserud","year":"1995","journal-title":"Br J Haematol"},{"issue":"8","key":"2023050514393302300_bib32","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/bloodadvances.2020003988","article-title":"Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis","volume":"5","author":"Higham","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2023050514393302300_bib33","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A\u00a0trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1784\/2049034\/blooda_adv-2022-008058-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1784\/2049034\/blooda_adv-2022-008058-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T19:14:02Z","timestamp":1701026042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1784\/486552\/Sickle-cell-disease-is-a-risk-factor-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008058","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}